-
1
-
-
49549107264
-
Pharmacogenetics of oral anticoagulants: a basis for dose individualization
-
10.2165/00003088-200847090-00002, 18698879
-
Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008, 47(9):565-594. 10.2165/00003088-200847090-00002, 18698879.
-
(2008)
Clin Pharmacokinet
, vol.47
, Issue.9
, pp. 565-594
-
-
Stehle, S.1
Kirchheiner, J.2
Lazar, A.3
Fuhr, U.4
-
2
-
-
15844427401
-
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy
-
10.1016/S0140-6736(96)01109-9, 8709780
-
Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996, 348(9025):423-428. 10.1016/S0140-6736(96)01109-9, 8709780.
-
(1996)
Lancet
, vol.348
, Issue.9025
, pp. 423-428
-
-
Palareti, G.1
Leali, N.2
Coccheri, S.3
Poggi, M.4
Manotti, C.5
D'Angelo, A.6
Pengo, V.7
Erba, N.8
Moia, M.9
Ciavarella, N.10
Devoto, G.11
Berrettini, M.12
Musolesi, S.13
-
3
-
-
0027291892
-
Bleeding complications in oral anticoagulant therapy: an analysis of risk factors
-
10.1001/archinte.1993.00410130073007, 8323419
-
van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993, 153(13):1557-1562. 10.1001/archinte.1993.00410130073007, 8323419.
-
(1993)
Arch Intern Med
, vol.153
, Issue.13
, pp. 1557-1562
-
-
van der Meer, F.J.1
Rosendaal, F.R.2
Vandenbroucke, J.P.3
Briët, E.4
-
4
-
-
22044433685
-
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
-
10.1182/blood-2005-01-0341, 15790782
-
Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005, 106(1):135-140. 10.1182/blood-2005-01-0341, 15790782.
-
(2005)
Blood
, vol.106
, Issue.1
, pp. 135-140
-
-
Bodin, L.1
Verstuyft, C.2
Tregouet, D.A.3
Robert, A.4
Dubert, L.5
Funck-Brentano, C.6
Jaillon, P.7
Beaune, P.8
Laurent-Puig, P.9
Becquemont, L.10
Loriot, M.A.11
-
5
-
-
55449133425
-
Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy
-
10.2217/14622416.9.9.1237, 18781852
-
Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, Mannucci PM, Peyvandi F. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008, 9(9):1237-1250. 10.2217/14622416.9.9.1237, 18781852.
-
(2008)
Pharmacogenomics
, vol.9
, Issue.9
, pp. 1237-1250
-
-
Spreafico, M.1
Lodigiani, C.2
van Leeuwen, Y.3
Pizzotti, D.4
Rota, L.L.5
Rosendaal, F.6
Mannucci, P.M.7
Peyvandi, F.8
-
6
-
-
62649171092
-
Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period
-
10.1038/clpt.2008.294, 19225451
-
Teichert M, van Schaik RH, Hofman A, Uitterlinden AG, de Smet PA, Stricker BH, Visser LE. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther 2009, 85(4):379-386. 10.1038/clpt.2008.294, 19225451.
-
(2009)
Clin Pharmacol Ther
, vol.85
, Issue.4
, pp. 379-386
-
-
Teichert, M.1
van Schaik, R.H.2
Hofman, A.3
Uitterlinden, A.G.4
de Smet, P.A.5
Stricker, B.H.6
Visser, L.E.7
-
7
-
-
66549110050
-
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
-
10.1182/blood-2008-09-176222, 19270263
-
Pérez-Andreu V, Roldán V, Antón AI, García-Barberá N, Corral J, Vicente V, González-Conejero R. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009, 113(20):4977-4979. 10.1182/blood-2008-09-176222, 19270263.
-
(2009)
Blood
, vol.113
, Issue.20
, pp. 4977-4979
-
-
Pérez-Andreu, V.1
Roldán, V.2
Antón, A.I.3
García-Barberá, N.4
Corral, J.5
Vicente, V.6
González-Conejero, R.7
-
8
-
-
42149188553
-
CYP4F2 genetic variant alters required warfarin dose
-
10.1182/blood-2007-11-122010, 2288721, 18250228
-
Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111(8):4106-4112. 10.1182/blood-2007-11-122010, 2288721, 18250228.
-
(2008)
Blood
, vol.111
, Issue.8
, pp. 4106-4112
-
-
Caldwell, M.D.1
Awad, T.2
Johnson, J.A.3
Gage, B.F.4
Falkowski, M.5
Gardina, P.6
Hubbard, J.7
Turpaz, Y.8
Langaee, T.Y.9
Eby, C.10
King, C.R.11
Brower, A.12
Schmelzer, J.R.13
Glurich, I.14
Vidaillet, H.J.15
Yale, S.H.16
Qi Zhang, K.17
Berg, R.L.18
Burmester, J.K.19
-
9
-
-
70350754462
-
A genome-wide association study of acenocoumarol maintenance dosage
-
10.1093/hmg/ddp309, 19578179
-
Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009, 18(19):3758-3768. 10.1093/hmg/ddp309, 19578179.
-
(2009)
Hum Mol Genet
, vol.18
, Issue.19
, pp. 3758-3768
-
-
Teichert, M.1
Eijgelsheim, M.2
Rivadeneira, F.3
Uitterlinden, A.G.4
van Schaik, R.H.5
Hofman, A.6
De Smet, P.A.7
van Gelder, T.8
Visser, L.E.9
Stricker, B.H.10
-
10
-
-
77953789313
-
Pharmacogenetics of acenocoumarol in patients with extreme dose requirements
-
Pérez-Andreu V, Roldán V, López-Fernández MF, Antón AI, Alberca I, Corral J, Montes R, García-Barberá N, Ferrando F, Vicente V, González-Conejero R. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost 2010, 8(5):1012-1017.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.5
, pp. 1012-1017
-
-
Pérez-Andreu, V.1
Roldán, V.2
López-Fernández, M.F.3
Antón, A.I.4
Alberca, I.5
Corral, J.6
Montes, R.7
García-Barberá, N.8
Ferrando, F.9
Vicente, V.10
González-Conejero, R.11
-
11
-
-
17644428069
-
Patients with an APOE epsilon4 allele require lower doses of coumarin anticoagulants
-
10.1097/01213011-200502000-00002, 15861030
-
Visser LE, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Patients with an APOE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 2005, 15(2):69-74. 10.1097/01213011-200502000-00002, 15861030.
-
(2005)
Pharmacogenet Genomics
, vol.15
, Issue.2
, pp. 69-74
-
-
Visser, L.E.1
Trienekens, P.H.2
De Smet, P.A.3
Vulto, A.G.4
Hofman, A.5
van Duijn, C.M.6
Stricker, B.H.7
-
12
-
-
77951931834
-
Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements
-
10.1007/s00228-009-0768-7, 20020283
-
Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, Patsch W, Oberkofler H. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 2010, 66(3):253-260. 10.1007/s00228-009-0768-7, 20020283.
-
(2010)
Eur J Clin Pharmacol
, vol.66
, Issue.3
, pp. 253-260
-
-
Cadamuro, J.1
Dieplinger, B.2
Felder, T.3
Kedenko, I.4
Mueller, T.5
Haltmayer, M.6
Patsch, W.7
Oberkofler, H.8
-
13
-
-
36549030324
-
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
-
10.1161/CIRCULATIONAHA.107.737312, 17989110, Couma-Gen Investigators
-
Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, . Couma-Gen Investigators Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116(22):2563-2570. 10.1161/CIRCULATIONAHA.107.737312, 17989110, Couma-Gen Investigators.
-
(2007)
Circulation
, vol.116
, Issue.22
, pp. 2563-2570
-
-
Anderson, J.L.1
Horne, B.D.2
Stevens, S.M.3
Grove, A.S.4
Barton, S.5
Nicholas, Z.P.6
Kahn, S.F.7
May, H.T.8
Samuelson, K.M.9
Muhlestein, J.B.10
Carlquist, J.F.11
-
14
-
-
34548822941
-
Genetic-based dosing in orthopedic patients beginning warfarin therapy
-
10.1182/blood-2007-01-069609, 1975838, 17387222
-
Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007, 110(5):1511-1515. 10.1182/blood-2007-01-069609, 1975838, 17387222.
-
(2007)
Blood
, vol.110
, Issue.5
, pp. 1511-1515
-
-
Millican, E.A.1
Lenzini, P.A.2
Milligan, P.E.3
Grosso, L.4
Eby, C.5
Deych, E.6
Grice, G.7
Clohisy, J.C.8
Barrack, R.L.9
Burnett, R.S.10
Voora, D.11
Gatchel, S.12
Tiemeier, A.13
Gage, B.F.14
-
15
-
-
23044440450
-
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
-
10.1182/blood-2005-03-1108, 15947090
-
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106(7):2329-2333. 10.1182/blood-2005-03-1108, 15947090.
-
(2005)
Blood
, vol.106
, Issue.7
, pp. 2329-2333
-
-
Sconce, E.A.1
Khan, T.I.2
Wynne, H.A.3
Avery, P.4
Monkhouse, L.5
King, B.P.6
Wood, P.7
Kesteven, P.8
Daly, A.K.9
Kamali, F.10
-
16
-
-
34548096907
-
Use of genetic and nongenetic factors in warfarin dosing algorithms
-
10.2217/14622416.8.7.851, 18240910
-
Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 2007, 8(7):851-861. 10.2217/14622416.8.7.851, 18240910.
-
(2007)
Pharmacogenomics
, vol.8
, Issue.7
, pp. 851-861
-
-
Wu, A.H.1
-
17
-
-
34547138943
-
Evaluation of genetic factors for warfarin dose prediction
-
10.3121/cmr.2007.724, 1855340, 17456829
-
Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007, 5(1):8-16. 10.3121/cmr.2007.724, 1855340, 17456829.
-
(2007)
Clin Med Res
, vol.5
, Issue.1
, pp. 8-16
-
-
Caldwell, M.D.1
Berg, R.L.2
Zhang, K.Q.3
Glurich, I.4
Schmelzer, J.R.5
Yale, S.H.6
Vidaillet, H.J.7
Burmester, J.K.8
-
18
-
-
60849097257
-
Estimation of the warfarin dose with clinical and pharmacogenetic data
-
2722908, 19228618, International Warfarin Pharmacogenetics Consortium
-
Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA, . International Warfarin Pharmacogenetics Consortium Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360(8):753-764. 2722908, 19228618, International Warfarin Pharmacogenetics Consortium.
-
(2009)
N Engl J Med
, vol.360
, Issue.8
, pp. 753-764
-
-
Klein, T.E.1
Altman, R.B.2
Eriksson, N.3
Gage, B.F.4
Kimmel, S.E.5
Lee, M.T.6
Limdi, N.A.7
Page, D.8
Roden, D.M.9
Wagner, M.J.10
Caldwell, M.D.11
Johnson, J.A.12
-
19
-
-
79851502859
-
A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery
-
Meijer K, Kim YK, Carter D, Schulman S. A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thromb Haemost 2011, 105(2):232-238.
-
(2011)
Thromb Haemost
, vol.105
, Issue.2
, pp. 232-238
-
-
Meijer, K.1
Kim, Y.K.2
Carter, D.3
Schulman, S.4
-
20
-
-
78650466131
-
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study
-
10.2217/pgs.10.162, 21174619
-
Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, Fogar P, Nisi A, Frigo AC, Moz S, Pelloso M, Plebani M. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 2011, 12(1):15-25. 10.2217/pgs.10.162, 21174619.
-
(2011)
Pharmacogenomics
, vol.12
, Issue.1
, pp. 15-25
-
-
Zambon, C.F.1
Pengo, V.2
Padrini, R.3
Basso, D.4
Schiavon, S.5
Fogar, P.6
Nisi, A.7
Frigo, A.C.8
Moz, S.9
Pelloso, M.10
Plebani, M.11
-
21
-
-
79953331201
-
Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes
-
10.1111/j.1538-7836.2011.04213.x, 21255252
-
Moreau C, Pautas E, Gouin-Thibault I, Golmard JL, Mahé I, Mulot C, Loriot MA, Siguret V. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost 2011, 9(4):711-718. 10.1111/j.1538-7836.2011.04213.x, 21255252.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.4
, pp. 711-718
-
-
Moreau, C.1
Pautas, E.2
Gouin-Thibault, I.3
Golmard, J.L.4
Mahé, I.5
Mulot, C.6
Loriot, M.A.7
Siguret, V.8
-
22
-
-
77951498679
-
Integration of genetic, clinical, and INR data to refine warfarin dosing
-
10.1038/clpt.2010.13, 2858245, 20375999
-
Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010, 87(5):572-578. 10.1038/clpt.2010.13, 2858245, 20375999.
-
(2010)
Clin Pharmacol Ther
, vol.87
, Issue.5
, pp. 572-578
-
-
Lenzini, P.1
Wadelius, M.2
Kimmel, S.3
Anderson, J.L.4
Jorgensen, A.L.5
Pirmohamed, M.6
Caldwell, M.D.7
Limdi, N.8
Burmester, J.K.9
Dowd, M.B.10
Angchaisuksiri, P.11
Bass, A.R.12
Chen, J.13
Eriksson, N.14
Rane, A.15
Lindh, J.D.16
Carlquist, J.F.17
Horne, B.D.18
Grice, G.19
Milligan, P.E.20
Eby, C.21
Shin, J.22
Kim, H.23
Kurnik, D.24
Stein, C.M.25
McMillin, G.26
Pendleton, R.C.27
Berg, R.L.28
Deloukas, P.29
Gage, B.F.30
more..
-
23
-
-
77955293789
-
A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants
-
10.1371/journal.pone.0011210, 2887839, 20585445
-
Verde Z, Ruiz JR, Santiago C, Valle B, Bandrés F, Calvo E, Lucía A, Gómez Gallego F. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 2010, 5(6):e11210. 10.1371/journal.pone.0011210, 2887839, 20585445.
-
(2010)
PLoS One
, vol.5
, Issue.6
-
-
Verde, Z.1
Ruiz, J.R.2
Santiago, C.3
Valle, B.4
Bandrés, F.5
Calvo, E.6
Lucía, A.7
Gómez Gallego, F.8
-
24
-
-
80051512500
-
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data
-
10.1093/eurheartj/ehr116, 21636598, for the EU-PACT Study Group
-
Van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, der Zee AH M-V, . for the EU-PACT Study Group Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011, 32(15):1909-1917. 10.1093/eurheartj/ehr116, 21636598, for the EU-PACT Study Group.
-
(2011)
Eur Heart J
, vol.32
, Issue.15
, pp. 1909-1917
-
-
Van Schie, R.M.1
Wessels, J.A.2
le Cessie, S.3
de Boer, A.4
Schalekamp, T.5
van der Meer, F.J.6
Verhoef, T.I.7
van Meegen, E.8
Rosendaal, F.R.9
der Zee, A.H.M.-V.10
-
25
-
-
84864103206
-
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease
-
10.1371/journal.pone.0041360, 3401172, 22911785
-
Borobia AM, Lubomirov R, Ramírez E, Lorenzo A, Campos A, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One 2012, 7(7):e41360. 10.1371/journal.pone.0041360, 3401172, 22911785.
-
(2012)
PLoS One
, vol.7
, Issue.7
-
-
Borobia, A.M.1
Lubomirov, R.2
Ramírez, E.3
Lorenzo, A.4
Campos, A.5
-
26
-
-
70649084116
-
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
-
10.2217/pgs.09.125, 19842940
-
VanSchie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, van der Zee AH M. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009, 10(10):1687-1695. 10.2217/pgs.09.125, 19842940.
-
(2009)
Pharmacogenomics
, vol.10
, Issue.10
, pp. 1687-1695
-
-
VanSchie, R.M.1
Wadelius, M.I.2
Kamali, F.3
Daly, A.K.4
Manolopoulos, V.G.5
de Boer, A.6
Barallon, R.7
Verhoef, T.I.8
Kirchheiner, J.9
Haschke-Becher, E.10
Briz, M.11
Rosendaal, F.R.12
Redekop, W.K.13
Pirmohamed, M.14
van der Zee, A.H.M.15
-
27
-
-
0027531953
-
A method to determine the optimal intensity of oral anticoagulant therapy
-
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69(3):236-239.
-
(1993)
Thromb Haemost
, vol.69
, Issue.3
, pp. 236-239
-
-
Rosendaal, F.R.1
Cannegieter, S.C.2
van der Meer, F.J.3
Briët, E.4
-
28
-
-
84872375978
-
A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism
-
pii: S0009-9120[12]00463-8
-
López-Parra AM, Borobia AM, Baeza C, Arroyo-Pardo E, Carcas AJ. A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism. Clin Biochem 2012, pii: S0009-9120[12]00463-8.
-
(2012)
Clin Biochem
-
-
López-Parra, A.M.1
Borobia, A.M.2
Baeza, C.3
Arroyo-Pardo, E.4
Carcas, A.J.5
-
29
-
-
23044505564
-
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
-
10.1111/j.1538-7836.2005.01204.x, 15842354
-
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3(4):692-694. 10.1111/j.1538-7836.2005.01204.x, 15842354.
-
(2005)
J Thromb Haemost
, vol.3
, Issue.4
, pp. 692-694
-
-
Schulman, S.1
Kearon, C.2
-
30
-
-
0019799332
-
A method for estimating the probability of adverse drug reactions
-
10.1038/clpt.1981.154, 7249508
-
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245. 10.1038/clpt.1981.154, 7249508.
-
(1981)
Clin Pharmacol Ther
, vol.30
, Issue.2
, pp. 239-245
-
-
Naranjo, C.A.1
Busto, U.2
Sellers, E.M.3
Sandor, P.4
Ruiz, I.5
Roberts, E.A.6
Janecek, E.7
Domecq, C.8
Greenblatt, D.J.9
-
31
-
-
39449086981
-
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study
-
10.1038/sj.clpt.6100316, 17851566
-
Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008, 83(3):460-470. 10.1038/sj.clpt.6100316, 17851566.
-
(2008)
Clin Pharmacol Ther
, vol.83
, Issue.3
, pp. 460-470
-
-
Caraco, Y.1
Blotnick, S.2
Muszkat, M.3
-
32
-
-
51449102801
-
Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry
-
10.1016/j.ejim.2007.06.026, 18848178, RIETE Investigators
-
Guijarro R, Montes J, Sanromán C, Monreal M, . RIETE Investigators Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. Eur J Intern Med 2008, 19(6):443-446. 10.1016/j.ejim.2007.06.026, 18848178, RIETE Investigators.
-
(2008)
Eur J Intern Med
, vol.19
, Issue.6
, pp. 443-446
-
-
Guijarro, R.1
Montes, J.2
Sanromán, C.3
Monreal, M.4
-
33
-
-
34447136188
-
Recurrent venous thromboembolism during coumarin therapy. Data from the computerized registry of patients with venous thromboembolism
-
and the RIETE Investigators
-
Lobo JL, Jiménez D, Orue MT, Grau E, Naufall D, Madridano O, Monreal M, . and the RIETE Investigators Recurrent venous thromboembolism during coumarin therapy. Data from the computerized registry of patients with venous thromboembolism. Brit J Haematol 2007, 138(3):400-403. and the RIETE Investigators.
-
(2007)
Brit J Haematol
, vol.138
, Issue.3
, pp. 400-403
-
-
Lobo, J.L.1
Jiménez, D.2
Orue, M.T.3
Grau, E.4
Naufall, D.5
Madridano, O.6
Monreal, M.7
-
34
-
-
0033599765
-
Acute pulmonary embolism: clinical outcomes in the Internacional Cooperative Pulmonary Embolism Registry (ICOPER)
-
10.1016/S0140-6736(98)07534-5, 10227218
-
Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the Internacional Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999, 353:1386-9.2. 10.1016/S0140-6736(98)07534-5, 10227218.
-
(1999)
Lancet
, vol.353
-
-
Goldhaber, S.Z.1
Visani, L.2
De Rosa, M.3
-
35
-
-
0037704209
-
Natural history of venous thromboembolism
-
I-22-I-30, 3
-
Kearon C. Natural history of venous thromboembolism. Circulation 2003, 107:I-22-I-30. 3.
-
(2003)
Circulation
, vol.107
-
-
Kearon, C.1
-
36
-
-
55549148457
-
Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry
-
for the RIETE Investigators
-
Nieto JA, Cámara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, Monreal M, . for the RIETE Investigators Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008, 100(5):789-796. for the RIETE Investigators.
-
(2008)
Thromb Haemost
, vol.100
, Issue.5
, pp. 789-796
-
-
Nieto, J.A.1
Cámara, T.2
Gonzalez-Higueras, E.3
Ruiz-Gimenez, N.4
Guijarro, R.5
Marchena, P.J.6
Monreal, M.7
-
37
-
-
33847006936
-
Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control Results From SPORTIF III and V
-
10.1001/archinte.167.3.239, 17296878
-
White HD, Michael G, Jan F, Scott K, Hung-Fat T, Steen H, Albers GW. Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control Results From SPORTIF III and V. Arch Intern Med 2007, 167:239-245. 10.1001/archinte.167.3.239, 17296878.
-
(2007)
Arch Intern Med
, vol.167
, pp. 239-245
-
-
White, H.D.1
Michael, G.2
Jan, F.3
Scott, K.4
Hung-Fat, T.5
Steen, H.6
Albers, G.W.7
-
38
-
-
57149140461
-
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
-
10.1161/CIRCULATIONAHA.107.750000, 18955670, ACTIVE W Investigators
-
Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, . ACTIVE W Investigators Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118(20):2029-2037. 10.1161/CIRCULATIONAHA.107.750000, 18955670, ACTIVE W Investigators.
-
(2008)
Circulation
, vol.118
, Issue.20
, pp. 2029-2037
-
-
Connolly, S.J.1
Pogue, J.2
Eikelboom, J.3
Flaker, G.4
Commerford, P.5
Franzosi, M.G.6
Healey, J.S.7
Yusuf, S.8
-
39
-
-
34249863576
-
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis
-
10.1503/cmaj.061523, 1867836, 17515585
-
Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007, 176(11):1589-1594. 10.1503/cmaj.061523, 1867836, 17515585.
-
(2007)
CMAJ
, vol.176
, Issue.11
, pp. 1589-1594
-
-
Oake, N.1
Fergusson, D.A.2
Forster, A.J.3
van Walraven, C.4
-
40
-
-
23844524855
-
Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome
-
10.1111/j.1538-7836.2005.01333.x, 15869588
-
van Dongen CJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005, 3(5):939-942. 10.1111/j.1538-7836.2005.01333.x, 15869588.
-
(2005)
J Thromb Haemost
, vol.3
, Issue.5
, pp. 939-942
-
-
van Dongen, C.J.1
Prandoni, P.2
Frulla, M.3
Marchiori, A.4
Prins, M.H.5
Hutten, B.A.6
|